Medical-device documentation
EU and FDA documentation compared
Also known as: MDR vs. FDA documentation · Technical documentation vs. FDA premarket submission
The EU and the United States both require evidence of safety and performance before a medical device is placed on the market, but they organize the documentation differently. In the EU, the manufacturer maintains technical documentation that a notified body assesses where the class requires it; in the United States, the manufacturer submits a premarket notification, De Novo request or premarket approval application to the FDA, which clears, grants or approves the device. Quality management, unique device identification, software change and post-market reporting follow parallel but distinct rules.
By knowledge.aitechdoc.world · Last reviewed
Definition
This article compares the documentation required for medical devices under the EU MDR and IVDR with that required by the US FDA under the Federal Food, Drug, and Cosmetic Act and Title 21 of the Code of Federal Regulations. It describes structures, not equivalence: meeting one framework does not establish conformity with the other.
Market access
- EU. Devices are classified (MDR classes I, IIa, IIb, III; IVDR classes A to D). Except for most class I and class A devices, a notified body assesses the quality management system and, depending on class, the technical documentation. The manufacturer draws up the EU declaration of conformity and affixes the CE marking.
- USA. Devices are classified (classes I, II, III). Most class II devices require a premarket notification (510(k)) demonstrating substantial equivalence to a predicate device; novel low- to moderate-risk devices can use the De Novo pathway; class III devices generally require premarket approval (PMA). The FDA reviews the submission itself. For 510(k) submissions, the electronic submission template eSTAR is the required format.
Quality management
The MDR and IVDR require a quality management system (Article 10(9)), commonly implemented through EN ISO 13485. Since February 2, 2026, the FDA's Quality Management System Regulation (21 CFR Part 820) incorporates ISO 13485:2016 by reference with additional FDA requirements, so one quality system can serve both markets. The former US record names (design history file, device master record, device history record) remain in use as practice terms.
Software and change
In the EU, significant changes to a device are assessed under the MDR or IVDR and, for high-risk AI systems, a substantial modification under the AI Act requires a new conformity assessment, while changes predetermined at the initial assessment and documented in the technical documentation are not substantial modifications. In the USA, a predetermined change control plan authorized with the marketing submission allows specified modifications without a new submission. The FDA's clinical decision support guidance determines which decision support functions are not devices; the EU has no equivalent exclusion and applies the definition of medical device software and Rule 11.
Identification and databases
Both frameworks use unique device identification. The EU registers devices and UDI data in EUDAMED; the US uses the Global Unique Device Identification Database (GUDID). The data elements overlap but are not identical.
Post-market
The EU requires post-market surveillance, periodic safety update reports or post-market surveillance reports, PMCF or PMPF, vigilance reporting of serious incidents and field safety corrective actions, and trend reporting. The USA requires medical device reporting under 21 CFR Part 803 and reports of corrections and removals under 21 CFR Part 806, and may order postmarket surveillance studies under section 522.
Comparison
| Aspect | EU (MDR/IVDR) | USA (FDA) |
|---|---|---|
| Primary record | Technical documentation (Annexes II and III), held by the manufacturer | Premarket submission (510(k), De Novo, PMA) reviewed by FDA, plus quality system records |
| Assessor | Notified body (class-dependent) | FDA |
| Quality system | Article 10(9), usually EN ISO 13485 | QMSR, ISO 13485:2016 by reference |
| Planned software change | Significant-change assessment; AI Act predetermined changes | PCCP (section 515C) |
| Decision support software | Medical device software, Rule 11 | Non-device CDS criteria (section 520(o)) |
| Device database | EUDAMED | GUDID |
| Incident reporting | Vigilance (Articles 87–92 MDR) | Medical device reporting (21 CFR Part 803) |
Limitations
Terms with the same name can have different scope: "intended purpose" (EU) and "intended use" and "indications for use" (USA) are related but not interchangeable, and a clinical evaluation report is not a substitute for the clinical data an FDA submission requires. Facts in this article are stated as of the review date.
Conclusion
A documentation system serving both markets keeps one body of evidence and several views on it: the EU technical file, the FDA submission and the quality system records, each with its own structure and vocabulary.
Further reading
- Regulation (EU) 2017/745 on medical devices (MDR) — EUR-Lex
- 21 CFR Part 820, Quality Management System Regulation — eCFR
- 21 CFR Part 803, Medical Device Reporting — eCFR
- Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions (final guidance) — U.S. Food and Drug Administration
- Clinical Decision Support Software (guidance) — U.S. Food and Drug Administration
- AccessGUDID, Global Unique Device Identification Database — U.S. National Library of Medicine and FDA
- EUDAMED, European database on medical devices — European Commission
Cite this article
knowledge.aitechdoc.world. “EU and FDA documentation compared.” Encyclopedia, AI TechDoc Knowledge. Last reviewed November 10, 2026. https://knowledge.aitechdoc.world/encyclopedia/medical-device-documentation/eu-and-fda-documentation-compared